Sedat Şen

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Maria Pia Sormani, Irene Schiavetti, Doriana Landi et al. · Multiple Sclerosis Journal · 2021 · 52 citations · Full text

Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trial

Serkan Özakbaş, Recai Türkoğlu, Yusuf Tamam et al. · Multiple Sclerosis and Related Disorders · 2018 · 49 citations

Cognitive Rehabilitation, Neuropsychology, Relapsing-remitting Multiple Sclerosis +11

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 37 citations · Full text